Skip to main content

Table 3 Evaluation of niclosamide-ivermectin combination treatments against SARS-CoV-2 in Calu-3 cells

From: Synergistic anti-SARS-CoV-2 activity of repurposed anti-parasitic drug combinations

Drug treatment

IC50

(μM)

Fold reduction of IC50 (single/combined)

Niclosamide-ivermectin

 Niclosamide

0.20

 

  Niclosamide + ivermectin 0.4 μM

ND

ND

  Niclosamide + ivermectin 0.2 μM

ND

ND

  Niclosamide + ivermectin 0.1 μM

0.084

2.38

  Niclosamide + ivermectin 0.05 μM

0.086

2.33

 Ivermectin

0.20

 

  Ivermectin + niclosamide 0.4 μM

ND

ND

  Ivermectin + niclosamide 0.2 μM

ND

ND

  Ivermectin + niclosamide 0.1 μM

0.055

3.64

  Ivermectin + niclosamide 0.05 μM

0.083

2.41

  1. ND not determined, cannot calculate IC50 with the least curve fit of the data sets